

Clarke, Mo

COLOMBIA

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 06-020917- -00005-0000

Fecha: 2009-10-09 14:46:15 Dep. 2020 NUECREACIONES
Tra. 11 PATENTE Y II Eve: 378 FASE NACIONAL I
Act. 444 RESPUESTA REQUE Folios: 25

P-1919

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

DIVISION DE NUEVAS CREACIONES

E.

S.

D.

Re: Expediente No. 06.020.917

Solicitud de patente a nombre de **NOVARTIS AG**

Yo, DILIA MARIA RODRIGUEZ D'ALEMAN identificada como aparece al pie de mi firma, domiciliada en la carrera 11 A No. 86-53, piso 6, obrando como apoderada de la sociedad **NOVARTIS AG**, domiciliada en Basilea Suiza, solicitante de la patente de la referencia, en respuesta al oficio No. 9379 notificado por fijación en lista el 14 de agosto de 2009, relacionado con el concepto técnico de fondo No. 02157, me permito informar lo siguiente:

Acompañamos copia informal del artículo de Blackburn C y Steven A. Kates "Solid-phase Synthesis of Cyclic Homodetic Peptides" publicado en Methods in Enzymology, vol 289. , páginas 175-198. 1997.

Con este artículo se proporciona cabal respuesta al requerimiento exigido por el señor Examinador con base en lo manifestado en el artículo 46 de la Decisión 486.

Señor Superintendente,

DILIA MARÍA RODRÍGUEZ D'ALEMAN
C.C. 41.654.882 de Bogotá.
T.P. 20824 CSJ

[9] Solid-Phase Synthesis of Cyclic Homodetic Peptides

By CHRISTOPHER BLACKBURN and STEVEN A. KATES

Introduction

There are two general classes of cyclic peptides: homodetic and heterodetic. Ring formation may occur to form the usual amide linkage between an amino and carboxylic acid function to give homodetic cyclic peptides, whereas any other linkages such as lactone, ether, thioether, and, most commonly, the disulfide bridge are referred to as heterodetic. The interest in cyclic homodetic peptides began in the late 1940s when the antibiotic gramicidin S was found to be a cyclic decapeptide.¹ Commercially available drugs such as the immunosuppressant cyclosporin indicate that research in this field continues. Many antibiotics and toxins have been shown to contain cyclic amino acid sequences that result in metabolic stability, increased potency, receptor selectivity, and bioavailability, and they are synthetically challenging. The constrained geometry of a cyclic peptide allows for conformational investigations such as determining the connection between primary and secondary structures of proteins and sequences related to protein folding and as selective metal ion chelating agents (ionophores). Initial work in this area focused on preparing peptides with a small ring size. Cyclic hexapeptides containing a proline to further restrict conformational possibilities were prepared and extensively studied. With the development of improved synthetic methods, larger ring sizes and more intriguing targets have been successfully attempted.

In the past, cyclic peptides have been prepared totally in solution² or by assembling the linear peptide in the solid phase,³ cleaving the peptide from the resin, and cyclizing in solution. Unfortunately, there are still limitations to the cyclization of peptides via classic solution-phase synthesis despite efforts to develop practical and convenient methods.⁴ For instance, a "doubling reaction" has been observed during ring closure.³ As a result, literature methods rely on suitably protected linear precursors, which are selectively activated and cyclized in solution under highly dilute conditions.

¹ R. J. Condesen, A. H. Gordon, A. J. P. Martin, and R. D. M. Synge, *Biochem. J.* **41**, 596 (1947).

² K. D. Kopple, *J. Pharm. Sci.* **61**, 1345 (1972).

³ A. E. Tonelli, in "Cyclic Polymers" (J. A. Semlyen, ed.), p. 261. Elsevier Applied Science, London, 1986.

⁴ D. S. Perlow, J. M. Erb, N. P. Gould, R. D. Tung, R. M. Freidinger, P. D. Williams, and D. F. Veber, *J. Org. Chem.* **57**, 4394 (1992).

Cyclodimerizations and cyclooligomerizations may also occur even under high dilution usually as unwanted side reactions but occasionally to benefit for certain symmetrical targets, as temperature, solvent, and the concentration and structure of the linear peptide are other important factors.^{2,4,5}

There are advantages to performing peptide cyclizations on solid phase rather than in solution. A pseudodilution phenomenon is achieved by having the linear peptide attached to a polymeric support. Intramolecular cyclization is favored over intermolecular because the solid support provides a large distance between chains.³ Furthermore, reactions can be driven to completion by the use of excess soluble reagents that can be removed by simple filtration and washing, and in an automated process.

There are three classic modes of medium- and long-range lactam cyclization of peptides. A ring may be formed via cyclization of the amino terminus to the carboxyl terminus. This mode of ring closure is called head to tail or end to end. Alternatively, the functional groups of side chains, usually the amino group of lysine or ornithine, can provide a method for lactam formation with the carboxylic acid of aspartic acid or glutamic acid. This type of cyclization is referred to as side chain-to-side chain or backbone-to-backbone cyclization. Lastly, cyclization can occur through a side chain such as the amino side-chain function of Lys/Orn to the carboxyl terminus. Alternatively, the carboxylic acid function of Asp/Glu can cyclize onto the amino terminus. Solid-phase syntheses of these classes of peptides have been attempted through different strategies outlined in Schemes 1, 2, and 3.

This article reviews the synthesis of cyclic homodetic peptides by solid-phase methods with an emphasis on solid supports, protecting group strategy, reagents, side reactions, and the emergence of cyclic peptide combinatorial libraries.⁶

Solid Supports

A wide range of polymeric supports has been successfully used to prepare cyclic peptides such as polystyrene (PS) resins and cellulose membranes.⁷ With the development of milder orthogonal protection schemes


⁵ M. Rothe, A. Sander, W. Fischer, W. Mastle, and B. Nelson, in "Peptides: Proceedings of the Fifth American Peptide Symposium" (M. Goodman and J. Meienhofer, eds.) p. 506. Wiley, New York, 1977.

⁶ For a recent review on solid-phase synthesis of cyclic peptides, see S. A. Kates, N. A. Solé, F. Albericio, and G. Barany, in "Peptides: Design, Synthesis and Biological Activity" (C. Basava and G. M. Anantharamaiah, eds.), p. 39. Birkhauser, Boston, 1994.

⁷ D. Winkler, A. Schuster, B. Hoffmann, and J. Schneider-Mergener, in "Peptides 1994: Proceedings of the Twenty-third European Peptide Symposium" (H. L. S. Maia, ed.), p. 485. Escom, Leiden, The Netherlands, 1995.


104

a. side chain to side chain




1. Removal of B^1 and B^2
2. Cyclization
3. Final deprotection and cleavage

b. N terminal to side chain



1. Removal of A and B
2. Cyclization
3. Final deprotection and cleavage

c. head to tail




1. Removal of A
2. Cyclization and concomitant release of protected peptide from the resin
3. Removal of protecting groups in solution


SCHEME 1. C-terminal anchoring strategy for different classes of cyclic peptides.

and more efficient reagents for cyclization, polyethylene glycol-polystyrene graft supports (PEG-PS) have been shown to be excellent resins.⁸ The PEG spacers allow complete solvation of the reactive sites, which increases coupling efficiency for both linear assembly and cyclization. Moreover, PEG-PS supports do exist that are compatible with both 9-fluorenylmethyloxycarbonyl (Fmoc)/*tert*-butyl (*t*Bu) and *tert*-butyloxycarbonyl (Boc)/ben-


⁸ G. Barany, F. Albericio, N. A. Solé, G. W. Griffin, S. A. Kates, and D. Hudson, in "Peptides 1992: Proceedings of the Twenty-second European Peptide Symposium" (C. H. Schneider and A. N. Eberle, eds.), p. 267. Escom, Leiden, The Netherlands, 1993.

I. Through carboxylic acid**a. head to tail**

1. Removal of A and B (usually two steps)
2. Cyclization
3. Final deprotection and cleavage


b. N terminal to side chain

1. Removal of A
2. Cyclization and concomitant release of peptide from the resin
3. Removal of protecting groups in solution

II. Through other amino acid side chain**a. head to tail**

1. Removal of A and B (usually two steps)
2. Cyclization
3. Final deprotection and cleavage

SCHEME 2. Side-chain anchoring strategy for different classes of cyclic peptides.



SCHEME 3. Backbone anchoring strategy for different classes of cyclic peptides.

zyl (Bzl) methods.⁹ Finally, PepsynK (polyamide-kieselguhr), a resin developed for continuous-flow instrumentation, has also been successfully used.¹⁰

Resin Loading

The amount of dimerization and oligomerization is dependent on the substitution level of the polymeric support. Plaué has prepared 4-methylbenzhydrylamine (MBHA) resins with an initial loading of 0.1–0.6 mmol/g and examined the cyclization of a model compound.¹¹ Analysis of the high-performance liquid chromatography (HPLC) data clearly indicate that as the resin substitution increases from 0.1 to 0.6 mmol/g, the percentage of cyclodimer increases from 8 to 19%. PEG-PS supports with 0.40 and 0.20 mmol/g substitutions have been used in conjunction with an Fmoc/

⁹ F. Albericio, J. Bacardit, G. Barany, J. M. Coull, M. Egholm, E. Giralt, G. W. Griffin, S. A. Kates, E. Nicolás, and N. A. Solé, in "Peptides 1994: Proceedings of the Twenty-third European Peptide Symposium" (H. L. S. Maia, ed.), p. 271. Escom, Leiden, The Netherlands, 1995.

¹⁰ C. Mendre, R. Pascal, and B. Calas, *Tetrahedron Lett.* **35**, 5429 (1994).

¹¹ S. Plaué, *Int. J. Pept. Protein Res.* **35**, 510 (1990).

*t*Bu/allyl strategy for the preparation of a head-to-tail cyclic peptide.¹² The product purity from the on-resin cyclization is greater with the lower loaded PEG-PS support. In contrast, when the repeating unit of gramicidin S is constructed on an oxime resin with 0.54 and 0.17 mmol/g loadings, the resin of lower loading gives more dimer due to interchain reactions.¹³ Cyclic monomeric peptide is formed at a faster rate and higher yield from the higher loaded resin.

Handles

Anchors that have been commonly employed for on-resin lactamization of cyclic peptides are shown in Fig. 1. The selection of a handle is governed by the protection strategy incorporated into a synthetic scheme. Initially, benzhydrylamine (BHA)- and MBHA-polystyrene resins were used because of their stability to strong acid (HF), which was commonly employed for final deprotection of side-chain protecting groups and release of the cyclic peptide from the resin.

The preparation of head-to-tail or a side chain-to-tail cyclic peptides requires "semipermanent" protection of the terminal carboxylic acid function (for definitions of the different protecting groups, see Protection Schemes). In standard linear assembly, the α -carboxylic acid is used for attachment to a solid support. Therefore, construction of these two classes of cyclic peptides demands side-chain anchoring of a trifunctional amino acid to a polymeric support. Side-chain anchoring on route to head-to-tail cyclic peptides has been accomplished by attachment of the ω -carboxyl groups of Asp or Glu to hydroxymethyl or benzhydrylamine resins.¹⁴ The linear peptide was assembled on a phenylacetamido (PAM) resin starting with attachment of Boc-Asp(OH)-OFm (where Fm is 9-fluorenylmethyl) followed by peptide chain elongation with Boc/Bzl amino acids. Tromelin *et al.* reported the synthesis of a head-to-tail cyclic peptide on MBHA resin via side-chain anchoring of Boc-Asp(OH)-OFm through an amide link.¹⁵ After acetylation of residual MBHA sites, the peptide chain was assembled using Boc/Bzl amino acids. Following removal of the N-terminal Boc group

¹² B. F. McGuinness, S. A. Kates, G. W. Griffin, L. W. Herman, N. A. Solé, J. Vágner, F. Albercio, and G. Barany, in "Peptides: Chemistry and Biology, Proceedings of the Fourteenth American Peptide Symposium" (P. T. P. Kaumaya and R. S. Hodges, eds.), p. 125. Mayflower Worldwide, Birmingham, UK, 1996.

¹³ M. Bouvier and J. W. Taylor, in "Peptide: Chemistry and Biology, Proceedings of the Twelfth American Peptide Symposium" (J. A. Smith and J. E. Rivier, eds.), p. 535. Escom, Leiden, The Netherlands, 1992.

¹⁴ P. Rovero, L. Quartara, and G. Fabbri, *Tetrahedron Lett.* **32**, 2639 (1991).

¹⁵ A. Tromelin, M. H. Fulachier, G. Mourier, and A. Ménez, *Tetrahedron Lett.* **33**, 5197 (1992).




FIG. 1. Handles used for the preparation of cyclic peptides.

and the C-terminal Fmoc group and cyclization, HF cleavage afforded a cyclic peptide in which the Asn residue was derived from the Asp group initially attached to the resin.

The side-chain anchoring strategy for head-to-tail cyclic peptides in Fmoc/*t*Bu-based chemistry was first conducted by McMurray¹⁶ by attaching Fmoc-Glu(OH)-ODmb (2,4-dimethoxybenzyl) to a 4-hydroxymethylphenoxycetylaminomethyl-resin for the preparation of cyclo(Ala-Ala-Arg-DPhe-Pro-Glu-Asp-Asn-Tyr-Glu). Albericio and co-workers applied an Fmoc/*t*Bu/allyl strategy to the preparation of the same sequence using four different starting resins: (a) Fmoc-Glu(OPAC-PEG-PS)-OAl (where PAC is *p*-alkoxybenzyl alcohol and Al is allyl) at positions Glu-6 and Glu-10, (b) Fmoc-Asp(OPAC-PEG-PS)-OAl at position Asp-7, and (c) Fmoc-

¹⁶ J. S. McMurray, *Tetrahedron Lett.* 32, 7679 (1991).

Asp(OPAL-PEG-PS)-OAl at position Asn-8. In strategy (c), Asn-8 was derived from an aspartic acid with its β -carboxylic acid bound to the resin via the 5-(4-aminomethyl-3,5-dimethoxyphenoxy)valeric acid (PAL) handle. All four strategies gave the desired peptide; the best yield and purity (71%) were obtained with the Asn-8 strategy, and the Glu-10 strategy gave the highest level of by-products.¹⁷

Side-chain anchoring an amino acid to a solid support has been accomplished most frequently through a carboxylic acid function, which restricts linear sequences to those containing Asx or Glx. As an extension to this approach, Alsina *et al.*¹⁸ prepared an active carbonate resin to which the side chain of Lys was attached. The novel solid support was prepared in quantitative yield by treatment of PAC resin with *N,N'*-disuccinimidyl carbonate and 4-dimethylaminopyridine (DMAP) followed by coupling with Fmoc-Lys-OAl in the presence of *N,N*-diisopropylethylamine (DIEA).

Procedure. PAC-PS resin is suspended in *N,N*-dimethylformamide (DMF), and disuccinimidyl carbonate (10 equivalent) and DMAP (1 equivalent) are added under Ar for 2 hr. The resin is filtered and washed with DMF. Fmoc-Lys-OAl (10 equivalent) is dissolved in DMF, added to the resin in the presence of DIEA (20 equivalent), and allowed to react for 4 hr at 25°. The Fmoc group is removed with piperidine-DMF followed by peptide chain elaboration. Allyl removal is carried out using 1.9 M Pd(PPh₃)₄ in dimethyl sulfoxide (DMSO)-tetrahydrofuran (THF)-0.5 N aqueous HCl-morpholine (2:2:1:0.1, by volume), for 150 min at 25°. Following Fmoc group removal, the resin is treated with benzotriazol-1-yl-oxytris(dimethylamino)phosphonium hexafluorophosphate (BOP)/1-hydroxy-7-azabenzotriazole (HOAt)/DIEA (5:5:10 equivalents) in DMF for 2 hr at 25° to effect cyclization. The product is cleaved from the resin with concomitant removal of protecting group side chains with reagent R (TFA-thioanisole-1,2-ethanedithiol-anisole, 90:5:3:2, by volume) for 2 hr at 25°.

The above methods rely on the concept of side-chain anchoring an amino acid to a resin via a carboxylic acid or amine function, which restricts the sequences that can be cyclized on a solid support. The BAL handle (backbone amide linker) has been developed for Fmoc/*t*Bu methods to attach a peptide chain via a backbone amide nitrogen.¹⁹ An example of

¹⁷ S. A. Kates, N. A. Solé, C. R. Johnson, D. Hudson, G. Barany, and F. Albericio, *Tetrahedron Lett.* **34**, 1549 (1993).

¹⁸ J. Alsina, F. Rabanal, E. Giralt, and F. Albericio, *Tetrahedron Lett.* **35**, 9633 (1994).

¹⁹ K. J. Jensen, M. F. Songster, J. Vágner, J. Alsina, F. Albericio, and G. Barany, in "Peptides: Chemistry and Biology, Proceedings of the Fourteenth American Peptide Symposium" (P. T. P. Kaumaya and R. S. Hodges, eds.), p. 30. Mayflower Worldwide, Birmingham, UK, 1996.

the use of this handle involves the attachment of Fmoc-(BAL-OH)Ala-OAl to MBHA resin. Using the BAL anchor, head-to-tail cyclic peptides devoid of a trifunctional amino acid residue can be readily constructed.

Anchoring the first amino acid to a PAM-type handle for the synthesis of head-to-tail cyclic peptides via a Boc/Bzl/OFm strategy has been investigated.²⁰ Coupling Boc-Asp(OH)-OFm to hydroxymethyl PAM resins with *N,N'*-diisopropylcarbodiimide (DIPCDI)/DMAP using various conditions gives low yields and high levels of racemization. Nucleophilic substitution of bromomethyl-Pam handles with the cesium and zinc salts of Boc-Asp(OH)-OFm substantially improves the anchoring yield and lowers the amount of racemization.

Protection Schemes

The success of solid-phase synthesis of cyclic peptides is based on the proper combination of temporary, semipermanent, and permanent protecting groups (Table I) and the corresponding methods for their removal (Fig. 2). Temporary groups are for *N*^α-protection; semipermanent groups are for Lys/Orn-Asp/Glu side-chain protection, and permanent groups are for side-chain protection and resin-peptide anchorage. Two or more classes of groups that are removed by differing chemical mechanisms in any order and in the presence of other classes is called an orthogonal protection scheme. This discussion is organized according to the following format: semipermanent/temporary/permanent/handle (anchoring strategy and class of cyclic peptide, based on Schemes 1, 2, and 3) accompanied with a brief experimental section.

Oxime/Boc/Bzl/oxime Handle (Scheme 1c)

A polystyrene-based resin frequently used is the *p*-nitrobenzophenone oxime-resin^{21,22} which acts as both a semipermanent and permanent protecting group for the C terminus. This resin provides a method for preparation of head-to-tail cyclic peptides with concomitant cleavage from the resin via intramolecular nucleophilic displacement of the anchoring linkage by the amine terminus of a peptide.^{23,24} This strategy requires *N*^α-Boc amino acids for linear chain elongation because oxime resins are not compatible with secondary amines used for *N*^α-Fmoc removal. To avoid premature cleavage of the peptide from the resin, coupling of amino acids is accom-

²⁰ M.-L. Valero, E. Giralt, and D. Andreu, *Tetrahedron Lett.* **37**, 4229 (1996).

²¹ W. F. DeGrado and E. T. Kaiser, *J. Org. Chem.* **45**, 1295 (1980).

²² W. F. DeGrado and E. T. Kaiser, *J. Org. Chem.* **47**, 3258 (1982).


²³ G. Ösapay, M. Bouvier, and J. W. Taylor, *Tetrahedron Lett.* **31**, 6121 (1990).

²⁴ G. Ösapay and J. W. Taylor, *J. Am. Chem. Soc.* **112**, 6046 (1990).

TABLE I
PROTECTING GROUPS FOR SOLID-PHASE CYCLIC PEPTIDES

Semipermanent	Structure	Removal	Temporary	Permanent	Final cleavage
¹⁸⁴ <i>t</i> Bu, Boc	$\begin{array}{c} \text{CH}_3 \\ \\ \text{H}_3\text{C}-\text{C}- \\ \\ \text{CH}_3 \end{array} \quad \begin{array}{c} \text{CH}_3 \\ \\ \text{H}_3\text{C}-\text{C}-\text{O}-\text{C}(=\text{O})- \\ \\ \text{CH}_3 \end{array}$	TFA	Fmoc	Bzl	HF
Fm-Fmoc	$\begin{array}{c} \text{Fm} \\ \\ \text{H}-\text{CH}_2- \end{array} \quad \begin{array}{c} \text{Fmoc} \\ \\ \text{H}-\text{CH}_2-\text{O}-\text{C}(=\text{O})- \end{array}$	Piperidine	Boc	Bzl	HF
Allyl-Aloc	$\text{H}_2\text{C}=\text{CH}-\text{CH}_2- \quad \text{H}_2\text{C}=\text{CH}-\text{CH}_2-\text{O}-\text{C}(=\text{O})-$	Pd(0)	Fmoc/Boc	<i>t</i> Bu/Bzl	TFA/HF
Dmb	$\text{H}_3\text{CO}-\text{C}_6\text{H}_3(\text{OCH}_3)_2-\text{CH}_2-$	1% TFA	Fmoc	<i>t</i> Bu	TFA

Dde		Hydrazine	Fmoc	<i>t</i> Bu	TFA
Dmab- <i>N</i> -ivDde		Hydrazine	Fmoc	<i>t</i> Bu	TFA
CAM		NaOH	Fmoc	<i>t</i> Bu	TFA
TMSE		Tetrabutylammonium fluoride (TBAF)	Fmoc	<i>t</i> Bu	TFA
Adpoc-OPp		1% TFA	Fmoc	<i>t</i> Bu	TFA



- a. Side-chain protecting groups and resin-peptide anchorage ("permanent")
 b. N^ε-Protecting group ("temporary")
 c. Lys-Asp/Glu side-chain protecting groups ("semipermanent")

FIG. 2. Protection scheme for synthesis of cyclic peptides.

plished with BOP in conjunction with *in situ* neutralization using DIEA. Although final products have been obtained in high purity, a limitation is that the lability of the oxime residue can result in peptide lost at each step, resulting in low yields.

Procedure. The linear peptide chain is assembled on Boc-Leu-oxime resin (0.11 mmol/g). The Boc protecting group is removed by treatment of the resin with trifluoroacetic acid (TFA)-CH₂Cl₂ (3:3, v/v) for 30 min. After washing, the appropriate Boc-amino acid (5 equivalent), BOP (5 equivalent), and DIEA (5 equivalent) in DMF are added to the resin and allowed to couple for 2 hr. Couplings of Boc-Asn-OH and Boc-Gln-OH are repeated using 2.5 equivalents of reactants. After the final coupling, the Boc group is removed from the N terminus as described above and the resin treated with DIEA (1.5 equivalent) in CH₂Cl₂ for 24 hr. The protected cyclic peptide is isolated from the solution phase and purified by chromatography.

The selection of the amino acid to be anchored to an oxime resin influences the yield and purity of the desired target. Cyclo[Arg(Tos)-Gly-Asp(OcHex)-Phg] (where Tos is 4-toluenesulfonyl, cHex is cyclohexyl, and Phg is phenylglycine) has been synthesized and the monomer to dimer ratio studied as a function of the order of attachment of the amino acids to the resin.²⁵ The highest yield of monomer is achieved when Phg is the C terminus residue, whereas Arg(Tos) gives the lowest yield.

Oxime resins in conjunction with phenacyl (Pac) and allyl (Al) protecting groups have been used for the preparation of protected side chain-to-side chain cyclic peptides.²⁶ The linear peptide is anchored to the oxime

²⁵ N. Nishino, M. Xu, H. Mihara, T. Fujimoto, Y. Ueno, and H. Kumagai, *Tetrahedron Lett.* **33**, 1479 (1992).

²⁶ A. Kapimiolu and J. W. Taylor, *Tetrahedron Lett.* **34**, 7031 (1993).

resin via the β -carboxyl group of Boc-Asp(OH)-OX, where X is phenacyl or allyl ester. Fmoc-Lys(Boc)-OH is incorporated as the final amino acid following peptide elongation. Deprotection of the side chain with TFA-CH₂Cl₂ (1:3, v/v) followed by neutralization with DIEA-CH₂Cl₂ (1:19, v/v), releases the peptide from the resin and gives the cyclized, fully protected peptide.

As an alternative approach, Richter *et al.* have used the reactivity of thioesters toward nucleophilic attack for the preparation of head-to-tail cyclic peptides without Asx or Glx residues.²⁷ S-Tritylthioglycolic acid has been attached to Phe-MBHA resin and deprotected to give a handle terminating in a thiol group. Coupling of the first amino acid to the free thiol is achieved using DIPCDI and DIEA in CH₂Cl₂ with minimal epimerization. A series of linear penta-, hexa-, and heptapeptides is assembled from the thiol function using Boc chemistry and cyclized in the presence of DIEA (3 equivalent) and DMAP (0.1 equivalent) in *N,N*-dimethylacetamide (DMA) for 2–7 days.

Fmoc-Fm/Boc/Bzl/BHA Handle (Scheme 1b)

Felix *et al.* have described the Boc/Bzl/Fmoc approach for the construction of side chain-to-side chain cyclic peptides.²⁸ Linear peptides are prepared on BHA-resin by Boc/Bzl chemistry using Boc-Asp(OFm)-OH and Boc-Lys(Fmoc)-OH as precursors to the lactam residue. The Fm-based side-chain protecting groups have been shown to be stable to DIEA-CH₂Cl₂ used in neutralization steps. Selective removal of these groups using piperidine-DMF (1:4, v/v), cyclization, and HF cleavage gives the desired product.

Procedure. Boc-[Asp⁸(OFm),Lys¹²[Asp⁸,Ala¹⁵]GRF(1–29)]-BHA-resin (0.4 mmol) is deprotected at the Asp side chain using piperidine-DMF (1:4, v/v) (once for 1 min and once for 20 min) and then washed successively with DMF, methanol, CH₂Cl₂, and methanol (1 min each). The peptide is cyclized by addition of BOP (2.5 equivalent) in DMF containing triethylamine (2.8 equivalent) three times for 4 hr until the resin gives a negative ninhydrin test. The cyclic peptide is cleaved from the resin by treatment with HF–1,2-ethanedithiol at 0° for 2 hr. The product is isolated by evaporation of HF, washing with ethyl acetate, extraction with TFA, evaporation, and trituration with ether.

²⁷ L. S. Richter, J. Y. K. Tom, and J. P. Burnier, *Tetrahedron Lett.* 35, 5547 (1994).

²⁸ A. M. Felix, E. P. Heimer, C. T. Wang, T. J. Lambros, A. Fournier, T. F. Mowles, S. Maines, R. M. Campbell, B. B. Wegrzynski, V. Toome, D. Fry, and V. S. Madison, *Int. J. Pept. Protein Res.* 32, 441 (1988).

Boc-tBu/Fmoc/Bzl/BHA Handle (Scheme 1c)

Schiller *et al.* have developed the first method for the preparation of side chain-to-side chain cyclic lactam peptides on BHA-resin incorporating *N*^α-Fmoc-amino acids with Bzl side-chain protecting groups for linear assembly and with Boc and *t*Bu protection for amino- and carboxylate-containing side chains for cyclization.²⁹ Removal of the Boc and *t*Bu side-chain protecting groups with TFA-CH₂Cl₂, neutralization using DIEA-CH₂Cl₂, cyclization, and subsequent HF treatment remove benzyl side-chain protecting groups and cleave the peptide from the solid support.

Later, Schiller *et al.* reported a procedure enabling the preparation of demanding and larger cyclic peptides.³⁰ The linear sequences are synthesized on MBHA-resin using *N*^α-Boc-amino acids and changing to *N*^α-Fmoc-amino acids with Boc and *t*Bu side-chain protection for Orn and Asp, respectively, for the lactam region. Removal of the side-chain protecting groups with TFA is followed by neutralization and cyclization. Removal of the *N*^α-Fmoc group allows for the completion of the chain elongation using Boc/Bzl chemistry. The cyclic peptide is obtained from the resin on HF treatment.

Procedure. The linear peptide is constructed on MBHA-resin with the terminal *N*^α-Fmoc of Orn retained. Treatment with TFA-CH₂Cl₂ (1:1, v/v) to remove the side chains of Orn and Asp residues is followed by neutralization using DIEA-CH₂Cl₂ (1:9, v/v). After washing with DMF, cyclization is conducted by addition of *N,N'*-dicyclohexylcarbodiimide (DCC) (5 equivalent) and 1-hydroxybenzotriazole (HOBt) (5 equivalent) in DMF over a period of several days adding fresh DCC and HOBt every 48 hr. The N-terminal Fmoc group is removed with piperidine-CH₂Cl₂ (1:1, v/v) and the final residue coupled in the usual manner. The peptide is released from the solid support with removal of the Bzl side-chain protecting groups with HF.

Dmb/Fmoc/tBu/PAC Handle (Scheme 2a)

The utility of 2,4-dimethoxybenzyl (Dmb) ester protection for the α-carboxylic acid of Glu in conjunction with side-chain anchoring has been reported.¹⁶ Following linear peptide chain elaboration, removal of the Dmb group is accomplished with TFA-CH₂Cl₂ (1:99, v/v), conditions which are compatible with *t*Bu and 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc) side-chain protecting groups but not with Trt (trityl) protection for Cys

²⁹ P. W. Schiller, T. M. Nguyen, and J. Miller, *Int. J. Pept. Protein Res.* **25**, 171 (1985).

³⁰ P. W. Schiller, T. M.-D. Nguyen, L. A. Maziak, B. C. Wilkes, and C. Lemieux, *J. Med. Chem.* **30**, 2094 (1987).

and His residues. *N*^α-Fmoc removal, cyclization, release of the peptide from the resin and removal of *t*Bu side chains with prolonged treatment with TFA-phenol, and gel filtration to remove oligomers give a monomeric cyclic peptide.

Procedure. Fmoc-Glu(OH)-ODmb is coupled to PAC-PS resin (0.45 mmol/g) using a DMAP-catalyzed symmetric anhydride procedure. After assembly of the desired linear sequence, the Dmb group is removed by treatment with TFA-CH₂Cl₂ (1:99, v/v, six times for 5 min). The Fmoc group is removed (piperidine-DMF, 1:4, v/v) and the peptide cyclized by addition of BOP/HOBt (3 equivalent) and *N*-methylmorpholine (NMM) (6 equivalent) for 5 hr. After DMF washing, the resin is cleaved by treatment with TFA-phenol (95:5, v/v), to give the cyclic peptide.

Alloc-Al/Fmoc/tBu/PAC-PAL Handle (Scheme 2a)

The synthesis of cyclic head-to-tail peptides by a three-dimensional orthogonal protecting strategy was accomplished independently by Trzeciak and Bannwarth³¹ and by Albericio and co-workers¹⁷ with an Fmoc/*t*Bu/allyl scheme. Allyl-based protecting groups for peptide synthesis have been introduced independently by Lyttle and Hudson³² and by Loffet and Zhang³³ and are removed smoothly and quantitatively with mild palladium-catalyzed transfer without the undesired back-alkylation side reactions that result when carbocations are generated. Furthermore, owing to their lower steric hindrance and less hydrophobic character, allyl derivatives couple more efficiently than do *t*Bu-based derivatives.

The Fmoc/*t*Bu/allyl strategy has become an attractive approach and is incorporated in a variety of sequences. The antibiotic bacitracin has been synthesized by initially attaching the side chain of L-Fmoc-Asp(OH)-OAl to PAL-PS.³⁴ Linear assembly, allyl removal with Pd(PPh₃)₄, acetic acid and triethylamine, cyclization, addition of the N-terminal thiazoline dipeptide, and cleavage afford the cyclic peptide.

The preparation of cyclic peptides on solid phase with Fmoc/*t*Bu/allyl-based methods has been automated.³⁵ Standard allyl removal uses a sus-

³¹ A. Trzeciak and W. Bannwarth, *Tetrahedron Lett.* **33**, 4557 (1992).

³² M. H. Lyttle and D. Hudson, in "Peptides: Chemistry and Biology, Proceedings of the Twelfth American Peptide Symposium" (J. A. Smith and J. E. Rivier, eds.), p. 583. Escom, Leiden, The Netherlands, 1992.

³³ A. Loffet and H. X. Zhang, in "Innovation and Perspectives in Solid Phase Synthesis: Peptides, Polypeptides and Oligonucleotides" (R. Epton, ed.), p. 77. Intercept, Andover, UK, 1992.

³⁴ J. Lee, J. H. Griffin, and T. Nicas, *J. Org. Chem.* **61**, 3983 (1996).

³⁵ S. A. Kates, S. B. Daniels, and F. Albericio, *Anal. Biochem.* **212**, 303 (1993).

pended palladium catalyst, which is not feasible on a batch and continuous-flow peptide synthesizer. Solvent conditions have been examined and optimized to solubilize the catalyst, prevent undesired Fmoc deblocking, and be compatible with sensitive amino acids (Trp and Met) and with glyco- and sulfopeptides. CHCl_3 -acetic acid-NMM (37:2:1, by volume), has proved to be most effective for the use in automated instruments, and the results give comparable purity to that obtained by performing the cyclization manually.

Procedure. Automated side-chain deblocking of the allyl group is performed by placing a vial containing $\text{Pd}(\text{PPh}_3)_4$ (125 mg) under Ar in the amino acid module following the last amino acid in the sequence. The catalyst is dissolved to a final concentration of 0.14 M in CHCl_3 -acetic acid-NMM (37:2:1, by volume), delivered to a 0.3 mmol/g substituted peptidyl-resin (500 mg), and recycled through the column for 2 hr. The column is washed with a solution of 0.5% DIEA and 0.5% sodium diethyldithiocarbamate in DMF (10 min, 6 ml/min) and DMF (10 min, 6 ml/min). The N^α -Fmoc group of the final amino acid is removed, and benzotriazol-1-yl-*N*-oxytrispyrrolidinophosphonium hexafluorophosphate (PyBOP)/HOBt (4 equivalent) is dissolved to a final concentration of 0.3 M in a solution of 0.6 M DIEA in DMF and delivered to the solid support. The cyclization is allowed to occur until the resin gives a negative ninhydrin test, and the resin is washed with DMF (15 sec, 3 ml/min) and CH_2Cl_2 (6 min, 3 ml/min). The cyclic peptide is cleaved from the resin using TFA-anisole-2-mercaptoethanol (95:3:2, by volume), for 2 hr and the filtrate collected. The resin is washed with TFA and the combined filtrates treated with ether and cooled to -70° . After removal of the supernatant, the precipitated cyclic peptide is washed with ether, dissolved in acetic acid, and lyophilized.

After assembly of a linear peptide on MBHA-resin (0.4 mmol/g) the N^α -allyloxycarbonyl (Alloc) protecting group is removed by addition of $\text{PdCl}_2(\text{PPh}_3)_2$ (0.04 equivalent) and acetic acid (3.5 equivalent) in CH_2Cl_2 (3 ml/g of resin).³⁶ Tributyltin hydride (3 equivalent) is then added and allowed to react for 5 min before washing with CH_2Cl_2 , triethylamine- CH_2Cl_2 (1:9, v/v), CH_2Cl_2 , methanol, and CH_2Cl_2 .

Dde/allyl/Fmoc/tBu/PAL Handle (Scheme 1a)

A branched, cyclic peptide has been prepared by Bloomberg *et al.*³⁷ with an Fmoc/tBu/allyl/1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (Dde)

³⁶ O. Dangles, F. Guibé, G. Balavoine, S. Lavielle, and A. Marquet, *J. Org. Chem.* **52**, 4984 (1987).

³⁷ G. B. Bloomberg, D. Askin, A. R. Gargaro, and M. J. A. Tanner, *Tetrahedron Lett.* **34**, 4709 (1993).

118

17

protection scheme. The first branch is assembled by sequential coupling of Fmoc-Lys(Dde)-OH, Fmoc-Ala-OH, Fmoc-Glu(OAl)-OH, and Fmoc-Cys(Trt)-OH to PAL-PEG-PS followed by acetylation. The Dde function is removed with hydrazine, and the second branch is added. Allyl removal of the carboxyl side chain of Glu, *N*^α-Fmoc removal, cyclization, and cleavage from the resin give the crude peptide, which is purified by HPLC.

Procedure. Following assembly of the appropriate linear peptide the Dde group is removed by flowing a 1.5% solution of hydrazine in DMF through the resin for 9 min. Elongation from the side chain is carried out with Fmoc-amino acids. Allyl removal is achieved by suspending the resin in DMSO-THF-0.5 M HCl-NMM (20:10:10:1, by volume) (5 ml/100 mg of resin) and Pd(PPh₃)₄ (0.15 to 1.0 equivalent based on resin substitution) for 3 hr in an inert atmosphere. The Fmoc group is removed and cyclization is carried out by treatment of the resin with 1.5 equivalents of *N*-[(1*H*-benzotriazol-1-yl)(dimethylamino)methylene]-*N*-methylmethanaminium hexafluorophosphate *N*-oxide (HBTU)/HOBt/NMM (1:1:2, by volume) in DMF (2 ml/100 mg resin) for 2 hr. The cyclic peptide is cleaved from the resin using TFA-1,2-ethanedithiol-phenol-water-triisobutylsilane (92:3:2:2:1, by volume) and the product isolated by precipitation with ether.

N-ivDde-Dmab/Fmoc/*t*Bu/PAC-PAL Handle (Scheme 1a,b)

To complement the Dde protecting group, 4-{*N*-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]amino}benzyl (ODmab) ester protection for the carboxylic acid function of Asp and Glu residues and the more sterically hindered 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl (*N*-ivDde) group for amine protection have been reported.³⁸ Both protecting groups are orthogonal to Fmoc/*t*Bu methods, and cleavage is achieved within minutes on treatment with hydrazine-DMF (1:49, v/v).

Procedure. Fmoc-Asp(ODmab)-OH is coupled to 2-chlorotrityl resin and the linear sequence assembled using Fmoc/*t*Bu method. The Dmab group is removed by reaction with hydrazine-DMF (1:49, v/v) for 9 min. Cyclization is carried out by addition of DIPCDI/HOAt in DMF and the product cleaved from the resin using TFA-CH₂Cl₂ (1:99, v/v).

CAM/Fmoc/*t*Bu/PAC Handle (Scheme 1b)

Starting with Fmoc-Trp-PepsynK resin, Mendre *et al.* have assembled a head-to-side chain cyclic peptide.¹⁰ To avoid aspartimide formation, dimer

³⁸ D. J. Evans, B. W. Bycroft, W. C. Chan, and P. D. White, in "Peptides 1996: Proceedings of the Twenty-fourth European Peptide Symposium" (R. Ramage, ed.), in press. Mayflower Worldwide, Birmingham, UK, 1996.

Fmoc-Asp([Z]-Dpr-CAM)-OH (CAM, carboxyamidomethyl) is prepared in solution and incorporated into the linear sequence. Hydrolysis of the CAM group is achieved with NaOH; cyclization and cleavage from the resin with concomitant removal of *t*Bu-based side-chain protecting groups give the desired target.

Procedure. The CAM side-chain protecting group is removed by treatment with NaOH (3 equivalent) in 2-propanol–water (7:3, v/v) for 1 hr at 25° followed by neutralization with 1.75 *N* acetic acid (5 equivalent) and washed with acetic acid in 2-propanol–water (7:3, v/v), 2-propanol–water (7:3, v/v), 2-propanol and diethyl ether. The linear peptide is cyclized by three successive treatments with *N*-[(1*H*-benzotriazol-1-yl)(dimethylamino)methylene]-*N*-methylmethanaminium tetrafluoroborate-*N*-oxide (TBTU)/HOBt (3 equivalent) and DIEA (6 equivalent) for 2 hr. After washing, side-chain protecting groups are removed and the product cleaved from the resin by treatment with reagent K (TFA–water–phenol–thioanisole-1,2-ethanedithiol, 34:2:2:1:1, by volume) for 1.5 hr at 25°.

TMSE/Fmoc/*t*Bu/PAL Handle (Scheme 1b)

The trimethylsilylethyl ester (TMSE) group has been used for side-chain carboxyl protection in a three-dimensional orthogonal scheme for preparing cyclic peptides on Rink amine resin.³⁹ Fmoc-Asp(OTMSE)-OH is first coupled to the resin following standard Fmoc/*t*Bu elongation to elaborate the linear sequence. Treatment of the resin-bound peptide with 1 *M* tetrabutylammonium fluoride (TBAF) in DMF removes both the TMSE side chain and the *N*^α-Fmoc group; cyclization and cleavage give the desired target.

Procedure. Fmoc-Asp(OTMSE)-OH is coupled to Rink amide resin using DCC/HOBt, and residual amino groups are capped by treatment with acetic anhydride. After construction of the linear sequence, treatment with 1 *M* TBAF in DMF for 20 min removes both the TMSE and *N*^α-terminal Fmoc protecting groups. Cyclization is carried out by treatment with BOP (10 equivalent) and DIEA (5 equivalent) in DMF for 4 hr. Treatment with reagent K removes the side-chain remaining protecting groups and releases the cyclic peptide from the resin.

Adpoc-OPp/Fmoc/*t*Bu/PAC-PAL Handle (Scheme 1a,b)

2-Phenyl-2-propyl (OPp) ester and 2-(1'-adamantyl)-2-propoxycarbonyl (Adpoc) carbamate protection for carboxylic acids and amines, respec-

³⁹ C. K. Marlowe, *Bioorg. Med. Chem. Lett.* 3, 437 (1993).

tively, have been introduced as a third level of orthogonality in Fmoc/*t*Bu methods.⁴⁰ Linear sequences are assembled on *p*-alkoxybenzyl alcohol and 5-amino-10,11-dihydro-5*H*-dibenzo[*a,d*]cycloheptenyl-2-oxyacetyl-Nle-methylbenzhydrylamine resins for C-terminal acids and amides, respectively, and the OPp and Adpoc protecting groups are removed with TFA-CH₂Cl₂ (1:99, v/v). Neutralization, on-resin cyclization, and final cleavage yield the desired targets in high purity.

Procedure. Adpoc and OPp deprotections are conducted by mixing the resin with TFA-CH₂Cl₂ (1:99, v/v) six times for 10 min. The resin is washed with CH₂Cl₂ (twice, 1 min), DIEA-CH₂Cl₂ (1:49, v:v, twice, 1 min), and DMF (three times, 1 min). The peptide is cyclized with TBTU (1.2 equivalent) and DIEA (1.8 equivalent) in DMF three times for 1.5 hr. Treatment of the resin with TFA-water-*p*-cresol-1,2-ethanedithiol-2-methylindole (75:5:5:12.5:2.5, by volume) gives the crude peptide.

Reagents for Cyclization

Once a protection scheme has been chosen and successfully incorporated into a synthetic strategy, the penultimate step for on-resin cyclization requires an efficient coupling reagent (Fig. 3). Initially, carbodiimides were used for ring closure. In the first report for the assembly of side chain-to-side chain cyclic peptides, representative opioid analogs were treated with DCC (5 equivalent) and HOBt (5 equivalent) in DMF over a period of several days, adding fresh DCC and HOBt every 48 hr, to give 6–22% yields.²⁹


A comparison of different activators for lactamization was studied by Felix *et al.*⁴¹ Cyclization of a linear peptidyl-resin with 6 equivalents of DCC/HOBt in DMF required 6 days for a negative ninhydrin test, but the cleaved product was contaminated with side products. Alternatively, treatment with 6 equivalent of BOP in DMF containing excess DIEA gave a purer product in 4 hr. Bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl)- and diphenylphosphoryl azide (DPPA)-mediated cyclizations gave even less efficient cyclization in comparison to DCC as measured by quantitative ninhydrin. In a similar study, Hruby *et al.* investigated the cyclization

⁴⁰ F. Dick, U. Fritschi, G. Haas, O. Hässler, R. Nyfeler, and E. Rapp, in "Peptides 1996: Proceedings of the Twenty-fourth European Peptide Symposium" (R. Ramage, ed.), in press. Mayflower Worldwide, Birmingham, UK, 1996.


⁴¹ A. M. Felix, C. T. Wang, E. P. Heimer, and A. Fournier, *Int. J. Pept. Protein Res.* 31, 231 (1988).




DCC




DIPCDI




HOBT




HOAt




HBTU




HATU




HAPyU



BOP



PyBOP



PyAOP

FIG. 3. Coupling reagents used for on-resin cyclization.

123

of model peptides.⁴² To facilitate ring closure and minimize cyclodimerizations, D-amino acids were incorporated in the design, and linear peptides were assembled on chloromethyl and MBHA resins at loadings of 0.2 to 0.45 mmol/g. For on-resin cyclizations, BOP was found to be superior to DIPCDI/HOBt and DPPA, and to solution methods in terms of product yield, purity, and reaction rate.

Plaué found that BOP/HOBt/DIEA-mediated cyclization of a model peptide occurred in 2 hr, whereas with DIPCDI/HOBt lactamization required 3 days for completion.¹¹ The same ratio of cyclic monomer to dimer was obtained, but the amount of polymeric material formed was greater when using the BOP-containing mixture. For the formation of large loop peptides, cyclodimerization occurs at high resin loading if the cyclization rate is slow (DIPCDI). Polymerization occurs at high loading when cyclization is fast (BOP).

McMurray *et al.* studied the side reactions of head-to-tail cyclizations of resin-bound peptides.⁴³ BOP/HOBt/DIEA-mediated cyclizations gave more racemization and oligomerization than DIPCDI/HOBt. In addition, oligomerization and racemization were resin dependent but solvent independent with DIPCDI (BOP in CH₂Cl₂ gave greater amounts of oligomer). Story and Aldrich found that HBTU-mediated on-resin cyclizations gave poor results due to formation of a tetramethylguanidinium (Tmg) Schiff base derivative of the ω -amino group of α,β -diaminopropionic acid (Dap).⁴⁴ BOP- and DIPCDI/HOBt-activated cyclizations gave higher yields, but the reaction proceeded more slowly.

Applications of 1-hydroxy-7-azabenzotriazole (HOAt) and its uronium {*N*-[(dimethylamino)-1*H*-1,2,3-triazolo[4,5-*b*]pyridin-1-ylmethylene]-*N*-methylmethanaminium hexafluorophosphate *N*-oxide (HATU)} and phosphonium [7-azabenzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP)] derivatives have been thoroughly examined for both solution and solid-phase peptide synthesis.⁴⁵ These reagents enhance coupling rates and yields, reduce racemization, and are suitable for the synthesis of difficult peptides such as those which incorporate hindered amino acids and hydrophobic peptides or involve the coupling of protected segments. To study the utility of azabenzotriazole derivatives, the linear

⁴² V. J. Hruby, F. Al-Obeidi, D. G. Sanderson, and D. D. Smith, in "Innovation and Perspectives in Solid Phase Synthesis: Peptides, Polypeptides and Oligonucleotides" (R. Epton, ed.), p. 197. SPCC, Birmingham, U.K., 1990.

⁴³ J. S. McMurray, C. A. Lewis, and N. U. Obeyesekere, *Pept. Res.* **7**, 195 (1994).

⁴⁴ S. C. Story and J. V. Aldrich, *Int. J. Pept. Protein Res.* **43**, 292 (1994).

⁴⁵ S. A. Kates, L. A. Carpino, and F. Albericio, in "Peptides: Chemistry and Biology, Proceedings of the Fourteenth American Peptide Symposium" (P. T. P. Kaumaya and R. S. Hodges, eds.), p. 893. Mayflower Worldwide, Birmingham, UK, 1996.

TABLE II
COMPARISON OF COUPLING REAGENTS
FOR THE LACTAMIZATION STEP OF
CYCLO(Asp-Tyr-DTrp-Val-DTrp-DTrp-Arg)

Coupling method	Linear (%)	Cyclic (%)	Purity (%)
PyAOP/HOAt	5	74	61
PyBOP/HOBt	5	69	51
HATU/HOAt	5	70	50
HBTU/HOBt	5	63	44

heptapeptide cyclo(Asp-Tyr-DTrp-Val-DTrp-DTrp-Arg) was cyclized. For this model, azabenzotriazole-based reagents performed slightly better than the benzotriazole analogs, with PyAOP producing the peptide in highest yield (74%) and purity (61%) (Table II).⁴⁶

Aldrich and co-workers surveyed several activating reagents for their efficiency of resin-bound lactam formation in the cyclic dynorphin A model.⁴⁷ Uronium-based reagents HBTU, HATU, and 1-(1-pyrrolidinyl-1*H*-1,2,3-triazolo[4,5-*b*]pyridin-1-ylmethylene) pyrrolidinium hexafluorophosphate *N*-oxide (HAPyU) gave low yields of desired product and a high formation of the linear alkyl guanidinium by-products even when a low concentration of reagent was used. HATU and HAPyU gave better results than HBTU, but the dipyrrolidinylguanidinium (Dpg) by-product from HAPyU was more difficult to remove during purification. On the contrary, the phosphonium-based reagents BOP, PyBOP, and PyAOP gave satisfactory yields of cyclic peptide, but the reactions progressed more slowly (3 days). PyXOP cyclizations were faster than those with BOP, but all phosphonium reagents gave similar yields of cyclic peptide, undesired linear starting peptide, linear peptide imide, and cyclodimer.

Zhang and Taylor examined solvent conditions for solid-phase cyclizations.⁴⁸ Solvent mixtures were chosen that combine high polarity with excellent resin swelling properties. For BOP/DIEA lactamization on a *p*-chloromethylbenzyl-polystyrene resin, optimal monomer-dimer ratios were obtained with DMSO-*N*-methylpyrrolidone (NMP) (1:4, v/v) > THF-NMP (35:65, v/v), DMF, and DMF-CH₂Cl₂ (1:1, v/v) > CH₂Cl₂-DMF (96:4, v/v).

⁴⁶ S. A. Kates, C. A. Minor, H. Shroff, R. C. Haaseth, S. Triolo, A. El-Faham, L. A. Carpino, and F. Albericio, in "Peptides 1994: Proceedings of the Twenty-third European Peptide Symposium" (H. L. S. Maia, ed.), p. 248. Escon, Leiden, The Netherlands, 1995.

⁴⁷ S. Arttamangkul, B. Arbogast, D. Barofsky, and J. V. Aldrich, *Lett. Pept. Sci.* **3**, 357 (1996).

⁴⁸ W. Zhang and J. W. Taylor, *Tetrahedron Lett.* **37**, 2173 (1996).

124

23

12521

Cyclic Peptide Libraries

Combinatorial libraries serve as a source of diverse potential therapeutic candidates and have become an important tool in the drug discovery field. Pioneering work involving the creation and screening of linear peptide libraries has expanded to the preparation of cyclic peptide libraries.⁴⁹ Spatola *et al.* coupled the side chain of Boc-Asp-OFm to a benzyl alcohol resin (Merrifield) using Mitsunobu conditions and then constructed combinatorial libraries of cyclic pentapeptides.⁵⁰ The linear chain was assembled using Boc-amino acids with the exception of the last amino acid, which was added as the Fmoc derivative. To avoid partial racemization of the C-terminal Asp residue during chain elongation, 1 equivalent of DIEA in the couplings was used. Removal of Fmoc and Fm groups was accomplished using piperidine-DMF (1:4, v/v). Initially cyclizations were accomplished using BOP/HOBt, but the final lactam bond was formed faster using BOP/HOAt activation. Cleavage of peptide mixtures from the resin was carried out using HF.

Mihara *et al.* prepared cyclic peptide mixtures using oxime-resin. The cyclic peptides contained ϵ -aminocaproic acid (Aca) as a flexible residue to enhance the cyclization step.⁵¹ The synthesis of cell adhesion inhibitors cyclo[Arg(Tos)-Gly-Asp(OcHex)-Ser(Bzl)-Aca] was accomplished by BOP/HOBt-induced coupling of Boc-amino acids to Aca-oxime resin. After removal of the N-terminal Boc group, cyclization was effected by treatment with acetic acid-DIEA. A combinatorial library based on this structure in which Ser was replaced by Lys, Gln, Ala, Glu, Pro, Val, Tyr, Phe, and Trp was constructed via both the "mix and split" and mixture methods. For the mix and split technique, the cyclic peptides were formed in almost equal amount throughout the coupling and cyclization reactions. The mixed protocol (0.3 equivalent of each amino acid) gave similar results except lower yields for Pro and Val.

Side Reactions

Although fluoride-labile protecting groups and linkers have been developed as an extra level of orthogonality, a side reaction was observed when peptidyl-resins were treated with tetrabutylammonium fluoride. For Glu(OtBu)- and Asp(OtBu)-containing peptides, fluoride ions were found

⁴⁹ K.-H. Wiesmüller, S. Feiertag, B. Fleckenstein, S. Kienle, D. Stoll, M. Herrmann, and G. Jung, in "Peptides and Nonpeptide Libraries—A Handbook" (G. Jung, ed.), p. 203. VCH, Germany, 1996.

⁵⁰ A. F. Spatola, K. Darlak, and P. Romanovskis, *Tetrahedron Lett.* **37**, 591 (1996).

⁵¹ H. Mihara, S. Yamabe, T. Niidome, and H. Aoyagi, *Tetrahedron Lett.* **36**, 4837 (1995).

to convert α -peptides to their corresponding γ - or β -rearranged sequence.⁵² Although HPLC, matrix-assisted laser desorption/time-of-flight (MALDI-TOF) mass spectrometry, and amino acid analysis are powerful techniques for peptide identification, the use of capillary zone electrophoresis (CZE) was required to detect this phenomenon.

In the synthesis of small loop peptides using Fmoc/Bzl amino acids by Plaué,¹¹ HF cleavage afforded the desired cyclic peptide and a second product that was identified to be the result of imide formation between Asp-146 and Phe-147. To avoid the succinimide side reaction, cyclohexyl side-chain protection of Asp-146 was incorporated into the linear sequence.

With Fmoc/Fm protecting groups, following standard treatment with piperidine-DMF (1:4, v/v), a wash with 0.4% concentrated HCl in DMF,¹⁷ HOBt in DMF,⁴³ or a tertiary amine⁵⁰ was recommended prior to cyclization. This step ensured complete removal of piperidine and avoided the formation of C-terminal piperidylamides as a by-product in the cyclization step. If DBU-piperidine-DMF (1:1:48, by volume) was used, the acid wash was not required.

Epimerization during linear assembly was identified to be problematic for strategies that include side-chain anchoring of Asp residues. Coupling with preactivated pentafluorophenyl esters or reducing the amount of base to 1 equivalent for BOP/HOBt significantly reduced the level of racemization.⁵⁰ The degree of racemization during on-resin cyclization is affected by the amino acid sequence.⁴³

⁵² S. A. Kates and F. Albericio, *Lett. Pept. Sci.* **1**, 213 (1994).

[10] Disulfide Bond Formation in Peptides

By IOANA ANNIS, BALAZS HARGITTAI, and GEORGE BARANY

Introduction

Disulfide bridges represent important evolutionarily conserved structural motifs in many biologically important peptides and proteins, including hormones, enzymes, growth factors, toxins, and immunoglobulins.¹⁻⁵ Intra-

¹ J. M. Thornton, *J. Mol. Biol.* **151**, 261 (1981).

² T. E. Creighton, *BioEssays* **8**, 57 (1988).

³ N. Srinivasan, R. Sowdhamini, C. Ramakrishnan, and P. Balaram, *Int. J. Pept. Protein Res.* **36**, 147 (1990).